Zollinger-Ellison syndrome screening: Difference between revisions
Jump to navigation
Jump to search
| (13 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}} {{AE}} {{MJK}} | |||
{{CMG}} {{AE}} {{MJK}}; {{ARK}} | |||
{{Zollinger-Ellison syndrome}} | {{Zollinger-Ellison syndrome}} | ||
==Overview== | ==Overview== | ||
Measurement of fasting [[serum]] [[gastrin]] levels is the single best screening test for Zollinger-Ellison syndrome (ZES). Other tests such as provocative tests include, the [[secretin]] stimulation test, [[calcium]] stimulation test, secretin-plus-calcium stimulation tests, [[bombesin]] test, and protein meal test. | |||
==Screening== | ==Screening== | ||
* | *Measurement of fasting [[serum]] [[gastrin]] levels is the single best screening test for Zollinger-Ellison syndrome (ZES). | ||
* | *It is advised not to take [[gastric]] antisecretory medications at the time of the test. | ||
*Serial multiple measurements on different days have | *Serial multiple measurements on different days have been advised as the fasting [[gastrin]] levels can fluctuate from day to day and may appear to be normal. | ||
* | *In untreated ZES, normal levels of serum gastrin are extremely rare (<1%). | ||
*Multiple endocrine neoplasia-type 1 (MEN 1) syndrome should be suspected if serum calcium levels are elevated. | *[[Multiple endocrine neoplasia type 1|Multiple endocrine neoplasia-type 1]] (MEN 1) syndrome should be suspected if serum [[calcium]] levels are elevated greater than 12.0 mg/dl accompanied with gastrinoma. | ||
**'''Gastric acid secretory test:''' ZES is suspected in patients with a basal acid output (BAO) is greater than 15 mEq/h. ZES is also suspected in patients with a prior [[vagotomy]] and partial [[gastrectomy]] whose basal acid output (BAO) is greater than 5 mEq/h. | |||
***Basal gastric secretory volume greater than 140 mL is considered highly sensitive and specific in patients without any prior gastric acid lowering surgery, | |||
***Gastric acid pH less than 2.0 in the presence of a large gastric volume greater than 140 mL over 1 hour is highly suggestive of ZES in patients without any prior gastric acid lowering surgery, | |||
*'''Provocative tests:''' <ref name="pmid17108779">{{cite journal |vauthors=Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT |title=Serum gastrin in Zollinger-Ellison syndrome: II. | **'''Provocative tests:''' <ref name="pmid17108779">{{cite journal |vauthors=Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT |title=Serum gastrin in Zollinger-Ellison syndrome: II. A prospective study of [[gastrin]] provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features |journal=Medicine (Baltimore) |volume=85 |issue=6 |pages=331–64 |year=2006 |pmid=17108779 |doi=10.1097/MD.0b013e31802b518c |url=}}</ref> | ||
***[[Secretin]] stimulation test <ref name="pmid23851430">{{cite journal |vauthors=Shah P, Singh MH, Yang YX, Metz DC |title=Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome |journal=Pancreas |volume=42 |issue=6 |pages=932–6 |year=2013 |pmid=23851430 |pmc=3712291 |doi=10.1097/MPA.0b013e3182847b2e |url=}}</ref> | |||
***[[Calcium]] stimulation test | |||
***Secretin-plus-calcium stimulation tests | |||
***[[Bombesin]] test | |||
***Protein meal test | |||
*Secretin stimulation test is the provocative test of choice because of its higher sensitivity. In this test, a 2-U/kg bolus of secretin is administered intravenously after an overnight fast, and serum levels of gastrin are determined at 0, 2, 5, 10, and 15 minutes. An increase in serum gastrin of greater than 200 pg/mL is diagnostic. | *[[Secretin]] stimulation test is the provocative test of choice because of its higher [[Sensitivity (tests)|sensitivity]]. In this test, a 2-U/kg bolus of [[secretin]] is administered intravenously after an overnight fast, and serum levels of [[gastrin]] are determined at 0, 2, 5, 10, and 15 minutes. An increase in serum [[gastrin]] of greater than 200 pg/mL is diagnostic. | ||
* | *Imaging studies such as [[Somatostatin receptor]] scintigraphy (SRS) is helpful in staging and localizing the [[gastrinoma]]. | ||
*Screening also helps in determining if the patient is fit to undergo surgery for tumor resection. | |||
==References== | ==References== | ||
Latest revision as of 16:20, 11 October 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]; Aravind Reddy Kothagadi M.B.B.S[3]
|
Zollinger-Ellison syndrome Microchapters |
|
Differentiating Zollinger-Ellison syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Zollinger-Ellison syndrome screening On the Web |
|
American Roentgen Ray Society Images of Zollinger-Ellison syndrome screening |
|
Risk calculators and risk factors for Zollinger-Ellison syndrome screening |
Overview
Measurement of fasting serum gastrin levels is the single best screening test for Zollinger-Ellison syndrome (ZES). Other tests such as provocative tests include, the secretin stimulation test, calcium stimulation test, secretin-plus-calcium stimulation tests, bombesin test, and protein meal test.
Screening
- Measurement of fasting serum gastrin levels is the single best screening test for Zollinger-Ellison syndrome (ZES).
- It is advised not to take gastric antisecretory medications at the time of the test.
- Serial multiple measurements on different days have been advised as the fasting gastrin levels can fluctuate from day to day and may appear to be normal.
- In untreated ZES, normal levels of serum gastrin are extremely rare (<1%).
- Multiple endocrine neoplasia-type 1 (MEN 1) syndrome should be suspected if serum calcium levels are elevated greater than 12.0 mg/dl accompanied with gastrinoma.
- Gastric acid secretory test: ZES is suspected in patients with a basal acid output (BAO) is greater than 15 mEq/h. ZES is also suspected in patients with a prior vagotomy and partial gastrectomy whose basal acid output (BAO) is greater than 5 mEq/h.
- Basal gastric secretory volume greater than 140 mL is considered highly sensitive and specific in patients without any prior gastric acid lowering surgery,
- Gastric acid pH less than 2.0 in the presence of a large gastric volume greater than 140 mL over 1 hour is highly suggestive of ZES in patients without any prior gastric acid lowering surgery,
- Provocative tests: [1]
- Gastric acid secretory test: ZES is suspected in patients with a basal acid output (BAO) is greater than 15 mEq/h. ZES is also suspected in patients with a prior vagotomy and partial gastrectomy whose basal acid output (BAO) is greater than 5 mEq/h.
- Secretin stimulation test is the provocative test of choice because of its higher sensitivity. In this test, a 2-U/kg bolus of secretin is administered intravenously after an overnight fast, and serum levels of gastrin are determined at 0, 2, 5, 10, and 15 minutes. An increase in serum gastrin of greater than 200 pg/mL is diagnostic.
- Imaging studies such as Somatostatin receptor scintigraphy (SRS) is helpful in staging and localizing the gastrinoma.
- Screening also helps in determining if the patient is fit to undergo surgery for tumor resection.
References
- ↑ Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT (2006). "Serum gastrin in Zollinger-Ellison syndrome: II. A prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features". Medicine (Baltimore). 85 (6): 331–64. doi:10.1097/MD.0b013e31802b518c. PMID 17108779.
- ↑ Shah P, Singh MH, Yang YX, Metz DC (2013). "Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome". Pancreas. 42 (6): 932–6. doi:10.1097/MPA.0b013e3182847b2e. PMC 3712291. PMID 23851430.